Shuet Fong Neong, Emma O. Billington, Stephen E. Congly – 23 November 2018 – Healthy sexual function is important to maintain a good quality of life but is frequently impaired in patients with cirrhosis. The degree of sexual dysfunction appears to be linked with the degree of hepatic dysfunction. In men, sexual dysfunction can be related to the hyperestrogenism of portal hypertension and/or to decreased testosterone resulting from testicular dysfunction.

Shuet Fong Neong, Emma O. Billington, Stephen E. Congly – 23 November 2018 – Healthy sexual function is important to maintain a good quality of life but is frequently impaired in patients with cirrhosis. The degree of sexual dysfunction appears to be linked with the degree of hepatic dysfunction. In men, sexual dysfunction can be related to the hyperestrogenism of portal hypertension and/or to decreased testosterone resulting from testicular dysfunction.

Elsa Solà, Cristina Solé, Pere Ginès – 23 November 2018

Esther A. Peterson, Zsuzsanna Polgar, Gnanapackiam S. Devakanmalai, Yanfeng Li, Fadi L. Jaber, Wei Zhang, Xia Wang, Niloy J. Iqbal, John W. Murray, Namita Roy‐Chowdhury, Wilber Quispe‐Tintaya, Alexander Y. Maslov, Tatyana L. Tchaikovskaya, Yogeshwar Sharma, Leslie E. Rogler, Sanjeev Gupta, Liang Zhu, Jayanta Roy‐Chowdhury, David A. Shafritz – 20 November 2018 – Hepatocyte transplantation is an attractive alternative to liver transplantation. Thus far, however, extensive liver repopulation by adult hepatocytes has required ongoing genetic, physical, or chemical injury to host liver.

Dagmar Kollmann, Nicolas Goldaracena, Markus Selzner – 18 November 2018

Alastair O’Brien – 17 November 2018 – Many studies have shown that 20% human albumin solution infusions improve circulatory function in patients with advanced liver disease, and this treatment is widely recommended and used by all hepatologists. However, it is more expensive than other crystalloids or colloids, and several countries suffer shortages of supply. This article examines whether other fluids might be considered for these patients.

Anna Suk‐Fong Lok – 15 November 2018 – Chronic hepatitis B virus (HBV) infection remains a major global health burden. Currently, two types of treatment, interferons (IFNs) and nucleos(t)ide analogues (NAs), have been approved. These treatments are effective in suppressing HBV replication and in decreasing the risk of developing cirrhosis, liver failure, hepatocellular carcinoma (HCC), and death. However, these treatments do not eliminate the virus, and the risk of HCC remains.

Débora Raquel Benedita Terrabuio, Marcio Augusto Diniz, Lydia Teofilo de Moraes Falcão, Ana Luiza Vilar Guedes, Larissa Akeme Nakano, Andréia Silva Evangelista, Fabiana Roberto Lima, Clarice Pires Abrantes‐Lemos, Flair José Carrilho, Eduardo Luiz Rachid Cancado – 14 November 2018 – Between 50% and 86% of patients with autoimmune hepatitis (AIH) relapse after immunosuppression withdrawal; long‐term immunosuppression is associated with increased risk of neoplasias and infections.

Maria G. Cardona‐Gonzalez, Jason D. Goldman, Lawrence Narayan, Diana M. Brainard, Kris V. Kowdley – 14 November 2018 – There are limited data on direct‐acting antiviral (DAA) treatment options for previously treated patients with recurrent genotype 3 (GT3) hepatitis C virus (HCV) after liver transplantation. Sofosbuvir/velpatasvir/voxilaprevir (SOF/VEL/VOX) is currently approved for treatment of HCV in patients with prior treatment with DAAs.

This lecture summarizes the current approach to understanding NASH pathogenesis, and how to translate recent advances into routine clinical care. Beginning with an overview of key pathogenic steps in development and progression of NASH, the program will also cover different therapeutic approaches for specific subsets of patients with NASH and related complications, and risk stratification of patients with respect to clinical outcomes.Michael W. Fried (Moderator) Arun J. Sanyal Arun J.